Therapeutic uses of smad protein inhibitors: Selective inhibition of specific TGF-beta activities.

@article{Laping1999TherapeuticUO,
  title={Therapeutic uses of smad protein inhibitors: Selective inhibition of specific TGF-beta activities.},
  author={Nicholas James Laping},
  journal={IDrugs : the investigational drugs journal},
  year={1999},
  volume={2 9},
  pages={
          907-14
        }
}
Recent advances in TGF-beta signaling biology have identified smad proteins as cytoplasmic mediators of TGF-beta receptor activation. Current evidence suggests that smad proteins are transcription factors whose activity is regulated through phosphorylation by TGF-beta type I receptors. Several isoforms of the smad proteins have been identified which confer in part selectivity for different members of the TGF-beta family of receptors as well as some selectivity for downstream effects of TGF-beta… CONTINUE READING

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…